Current Issues in Molecular Biology (Jul 2024)

Frequency of Deleterious Germline Variants in HER2-Low Breast Cancer Patients Using a Hereditary Multipanel Gene Testing

  • Janaina Pontes Batista Cassoli,
  • Ítalo Fernandes,
  • Leonardo Carvalho,
  • Milena Fernandes,
  • Ana Fernanda Centrone,
  • Letícia Taniwaki,
  • Rita de Cássia Lima,
  • Uelson Donizeti Rocioli Junior,
  • Igor Wanderley Reis Dias,
  • Patrícia Taranto,
  • Juliana Beal,
  • Fernanda Teresa de Lima,
  • Fernando Moura,
  • Miguel Cendoroglo,
  • Sergio Eduardo Alonso Araújo,
  • Pedro Luiz Serrano Uson Junior

DOI
https://doi.org/10.3390/cimb46080471
Journal volume & issue
Vol. 46, no. 8
pp. 7976 – 7985

Abstract

Read online

HER2-Low is defined as low levels of HER2 expression, based on a score of 1+ on immunohistochemical (IHC) assay or as an IHC score of 2+ and negative results on in situ hybridization (ISH or FISH). They are a heterogeneous population of breast cancers that vary in prognosis and sensitivity to systemic treatments. The frequency and clinical characteristics of pathogenic germline variants (PGVs) in HER2-Low breast cancer (BC) patients is not defined. We analyzed results from patients with BC who underwent multi-gene panel testing (MGPT) (maximum 145 genes) between 2018–2019. We reclassified HER-2 status accordingly. Relationships between the variables of interest were assessed by adopting the proportional regression Cox models. Of a total of 167 BC patients who underwent MGPT, half were hormone-receptor-positive. The median age was 45 years. About two thirds of the patients were in the earlier stage of BC. A total of 57% of the cases were reclassified as HER-2-negative or -Low. PGVs were found in 19% of the patients overall, as follows: seven BRCA1, four BRCA2, two ATM, one ATR, two CFTR, three CHEK2, one FANCA, one MERTK, one MLH1, three MUTYH, one RAD50, three RAD51C, one RECQL4, and two TP53 mutations. In HER2-Low, 26.5% of the patients had PGVs, and in the overall cohort, this was 19.8%. In conclusion, differences in the prevalence of deleterious germline mutations in HER2-Low BC patients compared to non-HER2-Low BC patients were identified. Similar alterations in BRCA were observed in this group of patients compared to the overall cohort. Germline genetic tests should be evaluated in larger cohorts of patients with HER2-Low status to better address the findings.

Keywords